Spruce Biosciences, Inc. (SPRB)
- Business Wire
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., September 03, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 4:30 p.m. ET.
- Zacks
Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates
Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 33.33% and 3.87%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif., August 12, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2024 and provided corporate updates.
